As companies with lung cancer immunotherapies process the small level detail they received on the outcome of August's PBAC meeting at which the committee considered simplifying their reimbursement, AstraZeneca has announced new and positive results from its yet-to-be-listed IMFINZI (durvalumab). …
Latest Video
New Stories
-
Research reveals no link between statins and memory loss
November 19, 2019 - - Latest News -
Rather than tinkering the push should be to start again
November 19, 2019 - - Comment -
More criticism of PHARMAC as actor passes away
November 19, 2019 - - Latest News -
Another confirmed industry leader for BioPharmaDispatch 2020
November 19, 2019 - - Latest News -
Industry better than most but more work required on gender pay gap
November 19, 2019 - - Latest News -
This system is about 'rationing' not 'valuing'
November 18, 2019 - - Latest News -
PHARMAC shifts following reports of another death
November 18, 2019 - - Latest News